Last Updated: 12 Nov 2024
Executive Summary
Caribou Biosciences Inc. (CRBU) is a clinical-stage biotechnology company developing novel cell therapies for the treatment of cancer and other diseases. The company's lead product candidate, CB-010, is a chimeric antigen receptor (CAR) T-cell therapy targeting CD19 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
Company Overview
Founded in 2011 and headquartered in Berkeley, California
Focuses on developing cell therapies using its proprietary CRISPR-Cas gene editing technology
Has a pipeline of product candidates in various stages of development, including CB-010, CB-011, and CB-012
Fundamental Analysis
Revenue: $11.475 million in TTM, down 0.914% YoY
Gross Profit: -$68.379 million in TTM
Diluted EPS: -$1.66 in TTM
Book Value: $3.105
Price-to-Sales Ratio: 22.02
Price-to-Book Ratio: 0.9
Technical Analysis
52-Week High: $8.33
52-Week Low: $1.5
50-Day Moving Average: $2.007
200-Day Moving Average: $3.381
Beta: 2.263
Short Term Outlook
The stock is trading below its 50-day moving average, indicating a bearish trend in the short term.
Analyst recommendations are mostly positive, with 7 out of 9 analysts rating the stock as a "Buy" or "Strong Buy."
The company's upcoming earnings report on March 8, 2023, will provide further insights into its financial performance and future prospects.
Long Term Outlook
Caribou Biosciences has a promising pipeline of cell therapies with the potential to address significant unmet medical needs in oncology.
The company's proprietary CRISPR-Cas technology could provide a competitive advantage in developing more effective and durable treatments.
The growing market for cell therapies and the company's strong partnerships with leading research institutions and pharmaceutical companies position it well for long-term growth.
Analyst Recommendations
Strong Buy: 3
Buy: 4
Hold: 2
Sell: 0
Strong Sell: 0
Conclusion
Caribou Biosciences is a promising biotechnology company with a strong pipeline of cell therapies and a proprietary gene editing technology. While the stock is currently trading in a bearish trend, analysts remain optimistic about its long-term prospects. Investors should consider the company's financial performance, technical indicators, and analyst recommendations to make informed investment decisions.
